Global Alzheimer's Therapeutics Market Analysis Report 2022: A Potential $15.6 Billion Market by 2030
August 30, 2022 06:08 ET | Research and Markets
Dublin, Aug. 30, 2022 (GLOBE NEWSWIRE) -- The "Global Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report by Product (Cholinesterase Inhibitors, Pipeline Drugs), by End Use, by...
Global Alzheimer Drugs Market Report 2022: A Market Valued at $6,537.0 Million in 2021 - Forecast to 2027
February 15, 2022 07:08 ET | Research and Markets
Dublin, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By...
National Down Syndrome Organizations Launch Joint Effort To Change CMS Proposal Concerning Coverage For New Class Of Alzheimer’s Treatments
February 04, 2022 10:47 ET | National Down Syndrome Society
Atlanta, GA., Bismarck, ND., Burlington, MA., Denver, CO., Hoffman Estates, IL, NY, NY, Rockport, ME, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Down Syndrome Affiliates in Action (DSAIA), GiGi’s Playhouse...
Global Alzheimer's Disease Market Report 2021-2030: Current Landscape of the Marketed, Clinical and Preclinical Molecules Available/Being Developed for Treatment
November 24, 2021 02:48 ET | Research and Markets
Dublin, Nov. 24, 2021 (GLOBE NEWSWIRE) -- The "Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and...
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
June 16, 2021 09:00 ET | Headlands Research
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- Headlands Research (, a global next-generation clinical research site organization, is pleased to have supported Biogen...
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 22, 2019 06:30 ET | Biogen Inc.
New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on...
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
March 21, 2019 07:00 ET | Biogen Inc.
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and...
Streetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug Candidate 
November 23, 2017 08:45 ET | Streetwise Reports Llc
SAN FRANCISCO, Nov. 23, 2017 (GLOBE NEWSWIRE) -- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's...